Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients | Zendy

Israel Molina | Zendy; Vicenç Falcó | Zendy; Manuel Crespo | Zendy; Cristina Riera | Zendy; Esteban Ribera | Zendy; Adrián Curran | Zendy; Jaume Carrió | Zendy; Montserrat Díaz | Zendy; S Villar del Saz | Zendy; Roser Fisa | Zendy; Paulo López-Chejade | Zendy; I Ocaña | Zendy; Albert Pahissa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

Author(s) -

Israel Molina,

Vicenç Falcó,

Manuel Crespo,

Cristina Riera,

Esteban Ribera,

Adrián Curran,

Jaume Carrió,

Montserrat Díaz,

S Villar del Saz,

Roser Fisa,

Paulo López-Chejade,

I Ocaña,

Albert Pahissa

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm294

Subject(s) - medicine , visceral leishmaniasis , secondary prophylaxis , amphotericin b , surgery , gastroenterology , leishmaniasis , immunology , antifungal , dermatology

Visceral leishmaniasis (VL) is characterized by frequent relapses in HIV-infected patients, even in those who receive secondary prophylaxis. The aim of our study was to evaluate the efficacy of liposomal amphotericin B (L-AMB) for secondary prophylaxis of VL in HIV-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research